Search Results

You are looking at 1 - 9 of 9 items for :

  • "farnesyltransferase inhibitor" x
  • Refine by Access: All x
Clear All
Full access

Novel Biospecific Agents for the Treatment of Myelodysplastic Syndromes

Jason Gotlib and Peter L. Greenberg

: 131 – 137 . 25 Karp JE Lancet JE Kauffmann SH . Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial . Blood

Full access

Developmental Therapeutics for Myelodysplastic Syndromes

Aung Naing, Lubomir Sokol, and Alan F. List

. Reuter CWM Morgan MA Bergmann L . Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000 ; 96 : 1655 – 1669 . 29. Kurzrock R Kantarjian HM Cortes J . Farnesyltransferase

Full access

New Agents in Chronic Myelogenous Leukemia

Jorge Cortes and Francis Giles

SH . Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial . Blood 2001 ; 97 : 3361 – 3369 . 36 Kurzrock R

Full access

Novel Agents for the Treatment of Acute Myeloid Leukemia in the Older Patient

Maria R. Baer and Ivana Gojo

. Lancet JE Gojo I Gotlib J . A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia . Blood 2007 ; 109 : 1387 – 1394 . 23. Raponi M Lancet JE Fan

Full access

Peripheral T-Cell Lymphomas–Not Otherwise Specified: A Shrinking Entity?

Presented by: Steven M. Horwitz

or follicular helper T-cell lymphomas. 9 There were responses in some rare T-cell lymphomas, such as gamma-delta T-cell lymphomas, but no responses in patients with PTCL-NOS. Finally, tipifarnib, a farnesyltransferase inhibitor, has been shown to

Full access

Therapy for Older AML Patients: The Role of Novel Agents and Allogeneic Stem Cell Transplant

Jeffrey E. Lancet and Sergio Giralt

[abstract] . Blood 2007 ; 110 : Abstract 818 . 27. Lancet JE Gojo I Gotlib J . A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia . Blood

Full access

Optimizing Therapy for Acute Myeloid Leukemia

Holbrook E. Kohrt and Steven E. Coutre

[abstract] . Blood 2005 ; 106 : Abstract 404 . 79. Lancet JE Gojo I Gotlib J . A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia . Blood

Full access

The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma

Paul G. Richardson, Teru Hideshima, Constantine Mitsiades, and Kenneth C. Anderson

. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma . Blood 2004 ; 103 : 3271 – 3277 . 112. Nguyen AN

Full access

Medullary Carcinoma

R. Michael Tuttle, Douglas W. Ball, David Byrd, Gilbert H. Daniels, Raza A. Dilawari, Gerard M. Doherty, Quan-Yang Duh, Hormoz Ehya, William B. Farrar, Robert I. Haddad, Fouad Kandeel, Richard T. Kloos, Peter Kopp, Dominick M. Lamonica, Thom R. Loree, William M. Lydiatt, Judith McCaffrey, John A. Olson Jr., Lee Parks, John A. Ridge, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, and Lori J. Wirth

, metastatic MTC, and with vandetanib in hereditary metastatic MTC. 74 , 75 In addition, clinical response was seen in 6 of 8 patients treated with a combination of sorafenib and the farnesyltransferase inhibitor tipifarnib. 76 Sunitinib was associated with